Navigation Links
Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry
Date:6/1/2009

mentary assets of Rosetta Biosoftware," said Peter Neupert, corporate vice president, Health Solutions Group, Microsoft. "The newly combined offering will enable customers to improve the management and analysis of genomic, biological and research data, helping to bring lifesaving drugs and therapies to market faster and accelerate the realization of personalized medicine."

Introduced in April 2009, Microsoft Amalga Life Sciences is a new software platform designed to transform health and life sciences research data into the critical knowledge needed for the discovery of new treatments. The platform helps organizations across the life sciences spectrum accelerate research and discovery efforts by automating the management and analysis of massive, heterogeneous research data. This gives scientists and researchers the opportunity to redesign, manage and control research processes to increase productivity, reduce errors and improve decision-making.

The deal is expected to close at the end of June 2009, and the new Amalga Life Sciences platform incorporating Rosetta Biosoftware technologies is slated to be available in early 2010. Microsoft is pursuing hiring Rosetta Biosoftware employees who can fill roles that are critical to the effective incorporation of Rosetta Biosoftware technologies into the Amalga Life Sciences platform. Until the deal is closed, Rosetta Biosoftware will continue to operate as a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck.

About Microsoft in Health

Microsoft is committed to improving health around the world through software innovation. Over the past 12 years Microsoft has steadily increased its investments in health, with a focus on addressing the challenges of health providers, health and social services organizations, payers, consumers, and life sciences companies worldwide. Microsoft closely collaborates with a broad ecosystem of partners and d
'/>"/>

SOURCE Microsoft Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Progeniq Joins Microsoft in Bio IT Alliance
2. Intrasphere Technologies Releases PharmaCM Submissions Management and Authoring Module Powered by Microsoft Office SharePoint Server 2007
3. CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards
4. Netsmart Technologies Announces Development Program on Microsoft for Local Public Health Clinic Management and Vital Records Software
5. Bioscience Company Chooses Microsoft Dynamics AX to Improve Support for Compliance With Industry Rules
6. Appature Announces onKey as an Innovative Platform for Creating Microsoft HealthVault-Compatible Applications
7. Microsoft scientist highlights urgent need for new computer models to address climate change
8. Waters Brings Advanced Laboratory Data Management to Microsofts BioIT Alliance
9. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
10. Surety, LLC Joins Microsoft BioIT Alliance
11. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... members will be attending Pharma Ed Resources upcoming educational seminar and training ... industry leading speakers, this timely conference will provide Updates & Case Studies on ...
(Date:9/1/2015)... , September 2, 2015 ... auf die Forschung und Entwicklung neuartiger Therapien ... chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält vom ... dass sein neues Medikament patentiert wird. Das ... Allergien bei Kindern verhindert und Entzündungen vorbeugt.   ...
(Date:9/1/2015)... 1, 2015 Prostate cancer is ... American men. One in seven men will be ... cases are diagnosed annually. That said, not every ... powerful new technique, MRI Fusion Biopsy, to more ... treating only the affected areas and monitoring ...
Breaking Biology Technology:Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4
... CryoLife, Inc., (NYSE: CRY ) ... today announced,that it has received 510(k) clearance ... its CryoValve(R) SG pulmonary human heart valve ... proprietary,SynerGraft technology is designed to remove allogeneic ...
... CHENGDU, China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Inc., ... modernized traditional Chinese medicine (TCM) based in Chengdu,China, ... of the Board of,Directors, will host a conference ... financial results., The conference call will take ...
... Feb 7 Dilon Technologies, makers of,a gamma imaging ... G. Moussa to the position of President and Chief ... in the medical device industry,having held a number of ... -- a health care corporation he ran as,CEO for ...
Cached Biology Technology:CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves 2CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Pulmonary Heart Valves 3Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST 2Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer' 2
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... 5, 2015 The biosensors market is proving ... penetration into newer sectors, and development of devices resulting ... space has seen the entry of multiple participants each ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... of the Global Biosensors Market ( http://www.frost.com/nee9 ), ...
(Date:7/31/2015)... de 2015 BGI llevará a cabo la 10ª ... al 25 de octubre de 2015, en ... su décimo aniversario este año. Desde su inauguración en ... reuniones anuales más influyentes del mundo en los campos ... científicas más dinámicas, entusiastas y amenas. ICG-10 ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... for a trial to investigate the safety of a ... Allergy and Infectious Diseases (NIAID), part of the National ... Rochester, NY, Baltimore and Los Angeles will enroll a ... part of the NIAID-sponsored Vaccine and Treatment Evaluation Units ...
... remains a challenging problem. Building classifiers based on ... the selection of non-redundant but relevant genes is ... enough to allow diagnosis even in regular clinical ... regulatory pathways. Here an entropy-based method is proposed ...
... rate of HIV infection, warn two senior doctors in an ... people worldwide, including over 2 million children, are now infected ... 2003. , The underlying reason for this continuing increase is ... write the authors. , For instance, the search for a ...
Cached Biology News:NIAID Initiates Trial of Experimental Avian Flu Vaccine 2
... loci identification through targeting resequencing. ... intensive assay validation/optimization, high throughput PCR ... customer-supplied samples and sequence alignment and ... rapid and highly accurate identification of ...
... Luciferase-based ENGENISTM (Entire Gene/cDNA or Isolated Sequence) ... a quantitative approach for evaluation of a ... as an efficient target for RNA interference ... are not perfect, leaving the probability of ...
... Stabilizer is a is a bovine protein-free ... product is an aqueous solution that contains ... buffered saline), pH 6.6 - 7.2. ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ...
... Mouse anti-Yersinia pestis F1 antigen, ... Applications: ELISA: Use at ... at an assay dependent dilution. WB: ... Predicted molecular weight: 18 kDa. Not ...
Biology Products: